Clinical trials
Colitis clinical trials
Below are recruiting colitis clinical trials, each written for real people, not researchers. We’re tracking 308 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07767370RecruitingEarly Phase 1
Two experimental drugs for chronic inflammatory diarrhea
This study tests two experimental capsules, ND-12 and H-6, given together to adults with long-term diarrhea caused by inflammation in the gut, such as active ulcerative colitis. It aims to see if the combination is safe and helps reduce diarrhea and inflammation.
Nanjing, JiangsuAges 18–75 - NCT07710287Recruiting
Using a protein test to measure inflammation in IBD
This study looks at a protein called claudin 2 in tissue samples from people with inflammatory bowel disease (IBD). The goal is to see if it can help doctors tell whether inflammation is active or inactive. This could lead to a more accurate way to check disease activity.
San Donato Milanese, MiAges 18 years+ - NCT06642883Recruiting
A supplement for gut health in ulcerative colitis remission
This study tests a supplement called ProLife 10 FORTE to see if it affects the natural balance of gut bacteria in people with ulcerative colitis (UC) that is in remission. If you have UC that is not active and you meet other health criteria, you may be able to join.
Padua, PaduaAges 18–75 - NCT07691138RecruitingPhase 4
Stopping acid-reducing pills in stable IBD
This study tests whether it is safe to stop taking acid-reducing pills (PPIs) for people with inactive IBD. If you have been on a PPI for over 6 months and your IBD is stable, you may be able to join.
NottinghamAges 16 years+ - NCT04305769RecruitingPhase 2
Alanyl-glutamine to help treat C. difficile diarrhea
This study tests whether the supplement alanyl-glutamine, given along with standard treatment, can improve outcomes for adults being treated for C. difficile infection (a cause of diarrhea). It may help the body recover better after antibiotics that usually treat C. difficile.
Charlottesville, VirginiaAges 18–105 - NCT07686757Enrolling by invitationPhase 4
Study of mirikizumab for ulcerative colitis and Crohn's disease
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
Sun City, ArizonaAges 21 years+ - NCT07686406Recruiting
IBD biomarker discovery study
This study collects blood, stool, tissue, and health information from people with inflammatory bowel disease (IBD), their relatives, and healthy volunteers to find patterns that may help diagnose or treat IBD better in the future.
Guangzhou, GuangdongAges 14 years+ - NCT07654751RecruitingPhase 4
Study of Tremfya in breast milk of breastfeeding women
This study measures how much Tremfya (guselkumab) gets into breast milk for women who are already taking it for conditions like psoriasis or arthritis and choose to breastfeed. It helps understand if the drug passes to the baby.
Chapel Hill, North CarolinaAges 18 years+ - NCT07647640Recruiting
Tracking flare-ups with your smartwatch
This study tests whether data from your own smartwatch or smartphone can help detect when your Crohn's disease or ulcerative colitis flares up. If you join, you'll use your own device, and no extra equipment will be provided.
's-HertogenboschAges 18 years+ - NCT07644117Recruiting
Personalized Anti-TNF Treatment for Inflammatory Bowel Disease
This trial tests a personalized approach to starting anti-TNF therapy—a common treatment for inflammatory bowel disease (IBD)—in patients who have never taken it before. The goal is to help doctors choose the right anti-TNF medication and dose based on each patient's individual characteristics.
Tel AvivAges 18 years+ - NCT07621783Recruiting
Blood protein levels and bowel disease activity in IBD
This study measures a blood protein called LRG and compares it to how active your inflammatory bowel disease (IBD) is during a planned scope procedure. The goal is to see if this blood test could help doctors assess disease activity more easily in the future.
BonheidenAges 16 years+ - NCT04191395Recruiting
Study of treatments for long-term inflammatory diseases
This study looks at how chronic inflammatory illnesses progress over time and how treatments affect symptoms and disease markers. You may be invited if you’re receiving care for certain bowel, joint, or skin inflammatory conditions at the hospital.
BesançonAges 18 years+ - NCT07593352Recruiting
Kidney Health in Inflammatory Bowel Disease Patients
This study compares kidney function between people with inflammatory bowel disease (IBD) and those without it. Researchers want to understand if IBD affects the kidneys and why, which could help protect kidney health in IBD patients.
Warsaw, WarszawaAges 18–80 - NCT07591012Recruiting
Probiotic Supplements for Ulcerative Colitis Remission
This trial tests whether taking sodium butyrate (a short-chain fatty acid) and a specific probiotic yeast called Kluyveromyces marxianus can help keep ulcerative colitis in remission and prevent flare-ups. You'd need to be in remission (symptom-free with no active inflammation) when you start.
PadovaAges 18–75 - NCT07582458RecruitingPhase 2/Phase 3
Modafinil for Fatigue in Controlled Inflammatory Bowel Disease
This trial tests whether modafinil (a wakefulness-promoting medication) can reduce severe fatigue in people with inflammatory bowel disease (IBD) whose disease is well-controlled. If you have persistent exhaustion despite your IBD being stable, this study may help determine if this medication works for you.
Arnhem, GelderlandAges 18–75 - NCT07564609Enrolling by invitation
Infliximab injection therapy outcomes in inflammatory bowel disease
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
AmiensAges 18 years+ - NCT07526519RecruitingPhase 1
Safety study of TL-003 for healthy adults and ulcerative colitis
This is an early-stage study testing a new drug called TL-003 to see if it's safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with ulcerative colitis (an inflammatory bowel disease) to understand if it might help reduce inflammation.
Perth, Western AustraliaAges 18–55 - NCT07532213Recruiting
Real-world outcomes of guselkumab for ulcerative colitis or Crohn's disease
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
BernAges 18 years+ - NCT07529236Recruiting
How Children's Bowel Disease Responds After Switching IBD Medications
This study follows children who had to stop one type of IBD medicine (anti-TNFα) because it caused a skin condition called psoriasis, and were switched to a different medicine called ustekinumab. Researchers want to see how well their bowel disease is controlled with the new treatment.
Nice, FranceAges 6–17 - NCT06756100Recruiting
Early inflammatory bowel disease study
This trial looks at early signs of inflammatory bowel disease (IBD) in adults who have had stomach or bowel symptoms for at least 3 weeks. It aims to understand how the disease progresses.
SantiagoAges 18–100 - NCT07524244Recruiting
Ketogenic and carnivore diets for IBD and rheumatoid arthritis
This study tests whether special diets (ketogenic or carnivore/meat-based) can help reduce inflammation and symptoms in people with inflammatory bowel disease or rheumatoid arthritis. You'll follow dietary guidelines for 3 weeks, then continue in the study while researchers track how you respond.
Charlottesville, VirginiaAges 18–64 - NCT07507513RecruitingPhase 2
New drug for moderate to severe ulcerative colitis
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07505030Enrolling by invitationPhase 1
Safety study of LYNC-101 in healthy adults
This trial tests a new medicine called LYNC-101 in healthy volunteers to see if it is safe and how the body processes it. If you are a generally healthy adult between 18 and 60, you may be able to help researchers learn about this potential treatment.
Adelaide, South AustraliaAges 3 weeks–2 months - NCT07487480Recruiting
Guselkumab for Crohn's after ustekinumab
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
Hangzhou, ZhejiangAges 18–75
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colitis?
- Yes. Clin2 currently lists 308 recruiting colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.